Adem Camilo, Soderberg Cheryl L, Cunningham Julie M, Reynolds Carol, Sebo Thomas J, Thibodeau Stephen N, Hartmann Lynn C, Jenkins Robert B
1Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
Int J Cancer. 2003 Nov 20;107(4):580-2. doi: 10.1002/ijc.11442.
Sporadic cancers and familial breast cancers are characterized by an increase in genetic instability. Little is known about whether mismatch repair defects accompany this genetic instability. We investigated invasive and/or in situ breast cancers from 30 women with deleterious BRCA1/2 mutations and unclassified variant BRCA1/2 alterations. Forty cases of sporadic breast cancers were also investigated, including 7 medullary carcinomas. Malignant and benign lesions were examined from all cases to better understand tumor progression. Automated immunohistochemistry, with antibodies directed against hMLH1 and hMSH2, was used to screen cases for possible mismatch repair defects. When loss of expression was noted, DNA ploidy was performed by cytomorphometry. DNA, after laser microdissection, was extracted from a majority of familial cases and their corresponding controls, and microsatellite instability analysis was performed. None of the familial or sporadic cases had loss of hMSH2 expression. All but one lesion, a DCIS arising in a deleterious BRCA2 mutation carrier, had loss of hMLH1 expression and a tetraploid profile by image cytomorphometry. There was no MSI in any explored lesions (n = 34), as determined by molecular analysis, including the DCIS with loss of hMLH1 expression. We conclude that DNA mismatch repair defects involving hMLH1 and hMSH2 underexpression are extremely rare events in sporadic and familial breast cancer. Mismatch repair gene mutations may be secondary random events in breast cancer progression.
散发性癌症和家族性乳腺癌的特征是基因不稳定性增加。关于错配修复缺陷是否伴随这种基因不稳定性,目前所知甚少。我们研究了30名携带有害BRCA1/2突变和未分类的BRCA1/2变异的女性的浸润性和/或原位乳腺癌。还研究了40例散发性乳腺癌,其中包括7例髓样癌。检查了所有病例的恶性和良性病变,以更好地了解肿瘤进展。使用针对hMLH1和hMSH2的抗体进行自动免疫组织化学分析,以筛查可能存在错配修复缺陷的病例。当发现表达缺失时,通过细胞形态计量学进行DNA倍体分析。在大多数家族性病例及其相应对照中,经过激光显微切割后提取DNA,并进行微卫星不稳定性分析。家族性或散发性病例中均未出现hMSH2表达缺失。除了一个病变(一名携带有害BRCA2突变的患者发生的导管原位癌)外,所有病变均出现hMLH1表达缺失,并通过图像细胞形态计量学显示为四倍体特征。通过分子分析确定,在任何所研究的病变(n = 34)中均未发现微卫星不稳定性,包括hMLH1表达缺失的导管原位癌。我们得出结论,涉及hMLH1和hMSH2低表达的DNA错配修复缺陷在散发性和家族性乳腺癌中极为罕见。错配修复基因突变可能是乳腺癌进展过程中的继发性随机事件。